This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignees: Novartis Ag, Novartis Pharma Ag. Active years: 2018-2025.
Company Filing History:
Years Active: 2018-2025
Title: The Innovations of Andreas Weichselberger
Introduction
Andreas Weichselberger is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of ocular medicine, particularly in the treatment of age-related macular degeneration and other intraocular neovascular disorders. With a total of 3 patents to his name, Weichselberger's work has the potential to greatly improve patient care and treatment outcomes.
Latest Patents
Weichselberger's latest patents include innovative methods for treating age-related macular degeneration. One of his methods provides a way to reduce the treatment burden for patients suffering from intraocular neovascular disorders. This method involves administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks. Another significant patent focuses on methods for treating ocular diseases with brolucizumab, which similarly aims to reduce the treatment burden for patients by utilizing a comparable dosing schedule.
Career Highlights
Throughout his career, Andreas Weichselberger has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Novartis Pharma AG. His experience in these organizations has allowed him to develop and refine his innovative approaches to treating ocular diseases.
Collaborations
Weichselberger has collaborated with several professionals in his field, including Peter Sallstig and James Warburton. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Andreas Weichselberger's contributions to ocular medicine through his patents and collaborations highlight his commitment to improving patient care. His innovative methods for treating age-related macular degeneration and other ocular diseases demonstrate the impact of his work in the medical field.